NASDAQ | ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology.
The fund is non-diversified.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| RVMD | Revolution Medicines Inc | Healthcare | Biotechnology | 6.40% |
| RHHBY | Roche Holding Ltd ADR | Healthcare | Drug Manufacturers - General | 5.08% |
| LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 4.82% |
| NOVN | Novartis AG | Healthcare | Drug Manufacturers - General | 4.28% |
| BBIO | BridgeBio Pharma Inc | Healthcare | Biotechnology | 4.27% |
| AZN | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 4.20% |
| NUVL | Nuvalent Inc | Healthcare | Biotechnology | 3.91% |
| SMMT | Summit Therapeutics PLC | Healthcare | Biotechnology | 3.91% |
| EXEL | Exelixis Inc | Healthcare | Biotechnology | 3.84% |
| BMY | Bristol-Myers Squibb Company | Healthcare | Drug Manufacturers - General | 3.74% |
| GMAB | Genmab AS | Healthcare | Biotechnology | 3.46% |
| MRUS | Merus BV | Healthcare | Biotechnology | 3.15% |
| ZLAB | Zai Lab Ltd | Healthcare | Biotechnology | 3.02% |
| IMGN | ImmunoGen Inc | Healthcare | Biotechnology | 3.00% |
| BPMC | Blueprint Medicines Corp | Healthcare | Biotechnology | 2.75% |
| 4568 | Daiichi Sankyo Co. Ltd. | Healthcare | Drug Manufacturers - General | 2.71% |
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 2.71% |
| BGNE | BeiGene Ltd | Healthcare | Biotechnology | 2.70% |
| LEGN | Legend Biotech Corp | Healthcare | Biotechnology | 2.69% |
| MRK | Merck & Company Inc | Healthcare | Drug Manufacturers - General | 2.65% |